tbuckley/cabot-search huggingface dataset:
Peer support to improve recovery following critical care discharge: a case-based discussion
Authors: Joanne McPeake, Theodore J Iwashyna, Helen Devine, Pamela MacTavish, Tara Quasim
Journal: Thorax (2017)

We report the case of a self-employed builder aged 58-years, with a medical history of ischaemic heart disease and type II diabetes. He was transferred to our intensive care unit (ICU) from another local hospital for treatment of gallstone pancreatitis. He stayed in critical care for 19 days, with a total hospital stay of 9 weeks. He and his wife have consented to the presentation of their case.

This patient required level three care (ICU care) for 3 days. He required level two care (high dependency care) for a further 16 days due to complications related to his acute kidney injury and pancreatitis. He was mechanically ventilated for 3 days with a worst P/F ratio of 150 mmHg and underwent renal replacement therapy for 8 days. As per standard practice in the ICU at the time, he was visited by physical therapy on 17 of his 19 ICU days. This patient has two children and a wife who works as a Nursery Teacher. After discharge from hospital, he returned to his own home.

At discharge from hospital, aerobic capacity was assessed using the incremental shuttle walk test. The patient scored a metabolic equivalent of 2.4 on this test (this represents an ability to undertake a low intensity exercise programme).1 Grip strength measurements were obtained and were 16 kg (right hand) and 12 kg (left hand), less than half of expected when compared with the population norm.2 

At home, further nutritional support from a nasogastric tube (NGT) was required. The patient also had significant fatigue, limb weakness, lethargy, decreased balance and shortness of breath. At 2 months post-discharge from hospital, neither he nor his wife had returned to work. In light of these problems, at 2 months post-ICU discharge, both the patient and his wife were invited to participate in Intensive Care Syndrome: Promoting Independence and Return to Employment …
PLZF-RARα Utilizes the Histone Methyl Transferase G9a/GLP and the Histone Demethylase LSD1 to Repress RARα Target Genes and Block Myeloid Differentiation
Authors: Itsaso Hormaeche, Kim L. Rice, Arthur Zelent, Melanie J. McConnell, Jonathan D. Licht
Journal: Blood (2008)
Dynamics of the global tumor immunome upon treatment with a novel anti-HER2 anthracycline based antibody drug conjugate in breast cancer
Authors: L. D'Amico, U. Haessler, U. Menzel, M. Buchi, N. Stefan, R. Beerli, U. Grawunder, S. Reddy, A. Zippelius
Journal: Annals of Oncology (2016)
RTHP-06. TREATMENT OF VESTIBULAR SCHWANNOMA WITH STEREOTACTIC RADIATION: A SINGLE INSTITUTION COMPARISON OF 3 DIFFERENT LINAC-BASED FRACTIONATION SCHEMAS
Authors: Uma Goyal, Benjamin Slane, Joel Grow, Christopher Morrison, Craig Hullet, Georgi Georgiev, Abhay Sanan, Baldassarre Stea
Journal: Neuro-Oncology (2016)

To evaluate and compare the radiographic and clinical outcomes of vestibular schwannomas treated at a single institution with single fraction stereotactic radiosurgery (SRS), 5 fractions of hypofractionated stereotactic radiotherapy (hSRT), and 25-30 fractions of stereotactic radiotherapy (cfSRT). Fifty-six patients treated with linac-based SRS (median 12.5 Gy), hSRT (25 Gy) or cfSRT (median 54 Gy) were retrospectively reviewed. Treatment technique was chosen based on the size of the tumor, its proximity to the brainstem, and potential risk of neurological sequelae. Median follow-up time was 55.2 months. The pretreatment median tumor diameter was significantly smaller for SRS (1.14 cm) compared with hSRT (1.7 cm) (p= 0.03) and cfSRT (1.91 cm) (p < 0.001). The overall local tumor control was 96.4% and by treatment group, it was 90% for cfSRT, 100% for hSRT, and 100% for SRS (p= 0.19). No patient experienced any grade 3 facial neuropathy. There was 3.6% incidence of grade 3 trigeminal neuropathy. Tumor regression was observed in 90% of cfSRT, 76.2% of hSRT, and 53.3% of SRS (p= 0.05). There was less transient expansion of tumors treated with cfSRT (5%) than with SRS (53.3%) or hSRT (28.6%) (p= 0.005). The median time to regression was 5.52 months for cfSRT, 14.2 months for hSRT, and 13.77 months for SRS (p= 0.34). All three regimens (cfSRT, hSRT, and SRS) demonstrated similar excellent local control with minimal toxicity. However, the ability of hSRT to treat larger tumors (or tumors abutting the brain stem) with comparable outcomes to SRS and the greater patient convenience when compared to cfSRT, suggest that hSRT may be an optimal treatment approach.
HE2100 (androst-5-ene-3β, 17β-diol), an Adrenal Hormone, Protects Rhesus Macaques from Lethal Total Body Irradiation (TBI)- Induced Severe Neutropenia and Thrombocytopenia.
Authors: Dwight R. Stickney, Charles Dowding, Simon Authier, Armando Garsd, Nanette Onizuka-Handa, Chris Reading, James Frincke
Journal: Blood (2005)
SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).
Authors: Andres Forero-Torres, STeven H. Bernstein, Ajay Gopal, Francine Foss, John P. Leonard, Joseph D. Rosenblatt, Nancy L. Bartlett, Bruce D. Cheson, Elliot Epner, Francisco J. Hernandez-Ilizaliturri, STephen J. Proctor, Pauline Brice, Herve Tilly, Corinne Haioun, Mats Jerkeman, Andre Bosly, Alessandro M. Gianni, Harald Holte, Premini Mahendra, Lutz Uharek, Jennie Lorenz, Jeremy Barton, Eric Sievers
Journal: Blood (2006)
An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.
Authors: Zheng Zhou, Alfred W. Rademaker, Leo I. Gordon, Ann S. LaCasce, Ann Vanderplas, Allison Crosby-Thompson, Andrew D Zelenetz, Gregory A. Abel, Maria A. Rodriguez, Auayporn Nademanee, Mark S. Kaminski, Myron S. Czuczman, Michael Millenson, Joyce Niland, Jonathan W. Friedberg, Jane N. Winter
Journal: Blood (2012)
First-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and tumoral immune cell infiltration data from the phase 2 COLET study
Authors: D.W. Miles, S.-B. Kim, T. Velu, J.A. García-Saenz, E. Tan-Chiu, J.H. Sohn, L. Dirix, J. Vanˇásek, M.V. Borms, J. Ilgado De Mingorance, M.-C. Liu, M.M. Moezi, M.F. Kozloff, J.A. Sparano, N. Xu, Y. Yan, M.J. Wongchenko, B. Simmons, V. McNally, A. Brufsky
Journal: Annals of Oncology (2016)
Screening Thousands of Drugs in Leukemia Patient Samples to Identify Novel Uses for Approved Drugs.
Authors: Teresa A Bennett, Sandra Sapia, Daniel Primo, Lilia Suarez, Santiago Lago, Maria Matoses, Ana Espinosa, Consuelo Tudela, Elena Arroyo, William Coyt Jackson, Alex Okun, Horacio Hector Lopez, Isolde Gornemann, Eva Diez, Josep M Roma, Jose Luis Dapena, Soledad Gallego Melcon, Jose Sanchez de Toledo, Ana Rosell, Santiago Del Castillo, Alicia Bailen, Ana Isabel Heiniger, Joaquin Díaz-Mediavilla, Felipe Prosper, Manuel Ramirez Sr., Macarena Ortiz, Marcos González, Alfonso Dominguez-Gil, Iñaki F Troconiz, Fernando Rodriguez de Fonseca, Enrique M Ocio, Andrew Saunders, Julieta Montejo, Luis Caveda, Alberto Orfao, Joan Ballesteros
Journal: Blood (2009)
Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis
Authors: J.-C. Soria, S.-W. Kim, Y.-L. Wu, K. Nakagawa, J.-J. Yang, M.-J. Ahn, J. Wang, J.C.-H. Yang, Y. Lu, S. Atagi, S. Ponce Aix, Y. Rukazenkov, R. Taylor, T.S.K. Mok
Journal: Annals of Oncology (2016)
Generation of CMV-Specific T-Lymphocytes for Adoptive Immunotherapy: A Comparison of Artificial Antigen-Presenting Cells and Autologous Dendritic Cells Pulsed with CMV-pp65 Protein-Spanning Pentadecapeptide Pools.
Authors: Wouter J.W. Kollen, Deepa Trivedi, Matthias Stephan, Michel Sadelain, Richard J. O’Reilly
Journal: Blood (2005)
Deficiency in TDAG51 Decreases Atherosclerotic Lesion Development in ApoE-Deficient Mice.
Authors: Gazi S. Hossain, Ji Zhou, Kenneth Maclean, Sarka Lhotak, Sudesh K. Sood, Hansa Patel, John Capone, J. Rho, Richard C. Austin
Journal: Blood (2006)
Re-importation of pharmaceuticals may be unsafe: Lessons learned from the RADAR assessment of erythropoietin (EPO)-associated pure red cell aplasia (PRCA)
Authors: C. L. Bennett, S. Luminari, A. R. Nissenson, S. A. Klinge, N. McWilliams, J. McKoy, D. W. Raisch, B. Kim, N. Casadevall, M. S. Tallman
Journal: Journal of Clinical Oncology (2004)

2512
EPID-10. ASSOCIATION OF KNOWN GLIOMA GERMLINE RISK SNPs WITHIN MOLECULARLY-DEFINED GROUPS
Authors: Jeanette Eckel-Passow, Paul Decker, Matthew Kosel, Thomas Kollmeyer, Gobinda Sarkar, Alissa Caron, Paige Bracci, Helen Hansen, Nils Madsen, Lucie McCoy, Annette Molinaro, Terri Rice, Kyle Walsh, Caterina Giannini, Ian Parney, Joseph Wiemels, John Wiencke, Beatrice Melin, Melissa Bondy, Daniel Lachance, Margaret Wrensch, Robert Jenkins
Journal: Neuro-Oncology (2016)

Germline alterations near TERC, TERT, EGFR, CCDC26, CDKN2A/B, VTI1A, ZBTB16, PHLDB1, POLR3B, ETFA, TP53 and RTEL1 are associated with glioma risk. Additionally, particular molecular groups of glioma are associated with SNPs with clinically-relevant odds ratios. For example, rs55705857 (CCDC26) is associated with >6-fold risk of developing gliomas that acquire IDH mutations. We recently demonstrated that five clinically-relevant groups of gliomas can be defined by TERT promoter mutation, IDH1/2 mutation and 1p/19q codeletion. Thus, we evaluated each of the currently known glioma risk SNPs with each of these five groups. Germline SNPs in 2157 glioma cases and 674 controls from Mayo Clinic and UCSF were genotyped using the custom Illumina Oncoarray developed by the Glioma International Case Control Consortium. Glioma cases were classified into five molecular groups based on TERT promoter mutation, IDH1/2 mutation and 1p/19q co-deletion. The groups were denoted as triple-negative, IDH-mutation only, TERT-mutation only, IDH and TERT mutations and triple-positive. Within each molecular group, additive logistic regression was used to assess the association of each SNP with disease status, adjusted for age, gender and site. Of the 2157 gliomas (867 GBM and 1290 nonGBM), 961 had sufficient molecular data for classification into a molecular group: 90 triple-negative, 238 IDH-mutation only, 410 TERT-mutation only, 36 IDH and TERT mutations and 187 triple-positive. Using alpha=0.01, TERT-mutation only gliomas were predominantly associated with TERT, CDKN2A/B and RTEL1 SNPs, while triple-positive gliomas were predominantly associated with ZBTB16 and ETFA SNPs. All groups with an IDH mutation were associated with the CCDC26 SNP and all molecular groups were associated with the TP53 SNP. Our results suggest that known glioma risk SNPs are often specific to a particular molecular subtype of glioma. We are currently obtaining additional cases and controls in order to increase statistical power for the smaller groups.
Four-Year Follow-Up after High-Dose Immunosuppressive Therapy (HDIT) for Severe Systemic Sclerosis (SSc).
Authors: Richard A. Nash, Peter McSweeney, Leslie Crofford, Kevin T. McDonagh, Maureen Mayes, J. Lee Nelson, Ted Gooley, Leona Holmberg, Howard Shulman, Mark Wener, Bernadette McLaughlin, Gretchen Henstorf, Jerry Molitor, James Seibold, Keith Sullivan, Daniel Furst
Journal: Blood (2006)
STMC-28. INTACT EGFR DEFINES HUMAN GERMINAL MATRIX AND GLIOBLASTOMA POPULATIONS WITH SHARED AND EPIGENETICALLY IMPRINTED STEM CELL PROPERTIES
Authors: Jessica Tome-Garcia, Rut Tejero-Villalba, Elena Zaslavsky, German Nudelman, Raymund Yong, Martin Walsch, Roland Friedel, Fiona Doetsch, Nadejda Tsankova
Journal: Neuro-Oncology (2016)

Epidermal growth factor receptor (EGFR) signaling is important for neural development and is frequently dysregulated in glioblastoma (GBM), but its developmental relationship to human gliomagenesis remains poorly understood. Using an EGF-ligand-binding strategy, we isolated EGFR+/– populations from fresh human germinal matrix (GM) and GBM tissues, enriching for cells with intact ligand-binding domain (EGFR+INTACT), and directly compared their downstream functional and molecular phenotypes. In both GM and GBM, only EGFR+ INTACT populations displayed stem cell properties in vitro, and in GBM, tumor initiation in vivo. Chromatin accessibility mapping revealed remarkable overlap between neoplastic and developing EGFR+ populations. Shared open chromatin regions annotated cell cycle and stemness gene sets and distinct regulatory motifs genome-wide, with footprints for ASCL1, SOX4/10, E2F1 and GABPA specifically at EGFR. Our study defines a novel population of EGFR+INTACT stem-like cells derived from fresh GM and GBM samples and implicates developmentally imprinted transcriptional regulators for their proliferation.
Identification of T Cell Epitope of ADAMTS13 in Thrombotic Thrombocytopenic Purpura Patients
Authors: Laurent Gilardin, Sandrine Delignat, Bernard Maillere, Bagirath Gangadharan, Ivan Peyron, Mathieu Ing, Nimesh Gupta, Yu Chun Lone, Agnes Veyradier, Jean-Baptiste Latouche, Srini Kaveri, Paul Coppo, Sébastien Lacroix-desmazes
Journal: Blood (2015)
c-Jun N-Terminal Kinase (JNK) Activation Failure Confers a New Mechanism of Anthracycline Resistance in Acute Myeloid Leukemia (AML).
Authors: Eleni D. Lagadinou, Panagiotis G. Ziros, Olga A. Tsopra, Kostas Dimas, Panagiotis Pantazis, Alexandros Spyridonidis, Nicholas C. Zoumbos
Journal: Blood (2007)
Apolipoprotein E Receptor 2′ Mediates Pathogenic Effects of Dimeric β2glycoprotein I and of Anti- β2glycoprotein I Antibodies in Vivo
Authors: Zurina Romay-Penabad, Rolf T Urbanus, Elizabeth Pappalardo, Yong Hwang, Ronald H.W.M. Derksen, Tuya Shilagard, Gracie Vargas, Maarten TT Pennings, Philip G De Groot, Silvia S Pierangeli
Journal: Blood (2008)
NIMG-17. DISCRIMINATION BETWEEN RADIATION INJURY AND BRAIN METASTASIS RECURRENCE BASED ON TEXTURAL FEATURE ANALYSIS OF FET PET – SUPERIOR TO STANDARD METHODS?
Authors: Philipp Lohmann, Gabriele Stoffels, Christian P Filss, Marion Rapp, Michael Sabel, Nadim J Shah, Karl-Josef Langen, Norbert Galldiks
Journal: Neuro-Oncology (2016)

Since the differentiation of radiation injury and tumor recurrence using standard MRI alone is difficult, we investigated the potential of textural parameters of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for this issue. Forty-seven patients (mean age, 55 ± 11 y) with single or multiple contrast-enhancing brain lesions (n=54) on MRI after radiotherapy of brain metastases (predominantly stereotactic radiosurgery) underwent FET PET in an ECAT EXACT HR+ scanner. VOIs were defined on summed images 20-40 min post-injection by a 3-dimensional auto-contouring process using a tumor-to-brain ratio (TBR) of 1.6. For each lesion, TBRs and time-activity curves of FET uptake and 59 textural parameters were determined using the CGITA toolbox (Fang et al., 2014 Biomed Res Int). Diagnostic accuracy of TBRs, kinetic patterns, time-to-peak, textural parameters and combinations thereof to discriminate between brain metastasis recurrence and radiation injury was evaluated by ROC analyses using histological results (21 lesions, 20 patients) or clinical course (33 lesions, 27 patients) as reference. The diagnostic accuracy increased from 81% for TBRmean alone to 85% when combined with the textural parameter Coarseness (sensitivity, 73%; specificity, 100%) or Short-zone emphasis (sensitivity, 77%; specificity, 96%). The accuracy of TBRmax alone was 83% and increased to 85% after combination with the textural parameters Coarseness (sensitivity, 73%; specificity, 100%), Short-zone emphasis (sensitivity, 77%; specificity, 96%) or Correlation (sensitivity, 77%; specificity, 96%). The analysis of the time-activity curves resulted in a diagnostic accuracy of 70% for the kinetic pattern alone and increased to 83% when combined with TBRmax. The accuracy of the time-to-peak was 67% and could not be further improved by combination with other parameters. Textural analysis in combination with TBRs may have the potential to increase the diagnostic accuracy for discrimination between brain metastasis recurrence and radiation injury, without the need for acquiring and analyzing more time-consuming dynamic FET PET scans.
Marrow Plasma Levels of Stromal Cell-Derived Factor-1α in Patients with Hematopoietic Malignancies Might Be Associated with the Migration of Leukemic Cells.
Authors: Jun Qian, Jiang Lin, Zi-xing Chen, Yong-jun Chen, Jiang-nong Cen, Yong-ning Zhang, Yong-hui Ji, Zhen Qian
Journal: Blood (2005)
norUrsodeoxycholic acid (norUDCA) improves cholestasis in primary sclerosing cholangitis (PSC) independent of ursodeoxycholic acid (UDCA) pre-treatment and response
Authors: Michael H. Trauner, Peter Fickert, Gideon Hirschfield, Gerald Denk, Istvan Altorjay, Hanns-Ulrich Marschall, Martti A. Farkkila, Christoph Schramm, Ulrich Spengler, Roger W. Chapman, Annika Bergquist, Erik Schrumpf, Frederik Nevens, Emina Halilbasic, Roland Greinwald, Markus Proels, Michael P. Manns
Journal: Hepatology (2016)
Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia
Authors: Guang Yang, Xia Liu, Jie Chen, Lian Xu, Nicholas Tsakmaklis, Jiaji Chen, Christopher J Patterson, Jorge J Castillo, Philip Cohen, Li Tan, Sara Buhrlage, Nathanael Gray, Steven P Treon
Journal: Blood (2015)
OS6.4 Molecular classification of meningiomas across all histological subtypes and grades
Authors: F. Sahm, D. T. W. Jones, M. Mittelbronn, M. Weller, W. Paulus, W. Wick, A. Unterberg, C. Herold-Mende, S. M. Pfister, A. von Deimling
Journal: Neuro-Oncology (2016)

The current WHO classification recognizes 15 subtypes of meningioma distributed across three grades of malignancy. Allocation to subtype is based on histological findings. For other brain tumors, molecular profiling has already identified novel subsets beyond histological definitions. Here, we set out to identify novel clinically relevant subgroups of meningioma and reliable molecular markers by methylation and mutational profiling of 416 samples across all subtypes.

Unsupervised clustering of methylation data from 450k array on 158 meningiomas (Discovery cohort) revealed six epigenetic subgroups. All cases were subsequently analyzed by targeted re-sequencing of a panel of genes. Selected cases of each group were subjected to exome-sequencing.

The most prominent epigenetic difference was found between a cluster encompassing the majority of grade III cases (“ANAP” cluster) and the remaining grade II and grade I samples. This subgroup carried mutations in chromatin-modifiers (e.g. CREBBP and others). Among the remaining five clusters, four were associated with distinct patterns of histology: One harboured predominantly meningothelial cases and several transitional cases, all with AKT1 or SMO mutations (“MEN”cluster). The second encompassed fibrous, psammomatous and transitional cases with NF2 mutations (“FIBRO” cluster). The third harboured angiomatous, metaplastic and microcystic cases, the majority with gain of chromosome 5 (“ANGIO” cluster). The fourth contained all cases of secretory meningioma with combined KLF4/TRAF7 mutations (“SECR” cluster). One cluster harboured samples of varying histology with a predominance of atypical grade II cases (“ATYP” for atypical). These cases were enriched for mutations in genes of the PI3K pathway other than AKT1. These subgroups hold true on an extended set of 416 samples and allocation to the subgroup was stable during progression. Importantly, these subgroups were associated with distinct clinical behavior. Stratification based on these subgroups allowed for more accurate prognostication than grading according to the WHO classification.

Collectively, these data identify stable genetic subgroups among meningiomas, providing the basis for a refinement of meningioma classification with molecular markers.
Phase II, singlearm, nonrandomized, and multicenter clinical trial of regorafenib (REG) as a single agent in the firstline setting for patients with metastatic and/or unresectable KIT/PDGFR wild-type GIST. A GEIS and ISG study
Authors: J. Martín Broto, E. Fumagalli, V. Martínez
Journal: Annals of Oncology (2016)
High IDH1 Expression Is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia
Authors: Qiu-Ling Ma, Jing-Han Wang, Yun-gui Wang, Chao Hu, Qi-Tian Mu, Meng-Xia Yu, Lei Wang, Dong-Mei Wang, Min Yang, Xiu-Feng Yin, Fei-Fei Chen, Sha-Sha Lu, Jian Chen, Zhi-Juan Zhu, Sai-Juan Chen, Jie Jin
Journal: Blood (2014)
Loss of muscle mass associated with the long term use of mTOR inhibitors
Authors: Bishal Gyawali, Tomoya Shimokata, Kazunori Honda, Chihiro Kondoh, Naomi Hayashi, Yasushi Yoshino, Naoto Sassa, Yasuyuki Nakano, Momokazu Gotoh, Yuichi Ando
Journal: Annals of Oncology (2016)
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial
Authors: U.B. Patel, G. Brown, I. Machado, J. Santos-Cores, C. Pericay, E. Ballesteros, A. Salud, M. Isabel-Gil, C. Montagut, J. Maurel, J. Ramón-Ayuso, N. Martin, R. Estevan, C. Fernandez-Martos
Journal: Annals of Oncology (2017)
Crusted Papules and Pustules on the Leg After a Trout Fishing Trip
Authors: Kathleen M. Nemer, George Denny, Caroline M. Mann
Journal: JAMA Dermatology (2017)

A woman in her 20s presented with aerythematous, crusted, edematous plaques and pustules with weeping of yellow exudate on her left leg 3 days after returning from a trout fishing trip in a freshwater lake. What is your diagnosis?
Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort
Authors: X. Pivot, J.-Y. Pierga, S. Delaloge, P. Fumoleau, H. Bonnefoi, T. Bachelot, C. Jouannaud, H. Bourgeois, M. Rios, P. Soulie, J.P. Jacquin, S. Lavau-Denes, P. Kerbrat, C. Faure Mercier, I. Pauporte, J. Gligorov, E. Curtit, J. Henriques, S. Paget-Bailly, G. Romieu
Journal: Annals of Oncology (2016)
Prospective Canadian Trial In Newly Diagnosed Multiple Myeloma Patients with t(4;14): Bortezomib-Based Therapy without ASCT
Authors: Donna E. Reece, Giovanni Piza Rodriguez, Andrew Belch, David Szwajcer, Michael J. Kovacs, Chaim Shustik, Nizar J Bahlis, Darrell J White, Mariela Pantoja, Christine Chen, Vishal Kukreti, Peter Anglin, Suzanne Trudel
Journal: Blood (2010)